目的 探討艾托格列凈聯(lián)合沙格列汀治療2型糖尿病的臨床療效。方法 選取2023年1月—2024年7月成都市龍泉驛區(qū)中醫(yī)醫(yī)院收治的100例2型糖尿病患者，按照隨機(jī)數(shù)字法分為對(duì)照組和治療組，每組各50例。對(duì)照組患者給予口服沙格列汀片，5 mg/次，1次/d。治療組在對(duì)照組的基礎(chǔ)上口服艾托格列凈片，5 mg/次，1次/d。兩組治療12周觀察效果。觀察兩組臨床療效，比較兩組餐后2 h血糖（2 hPBG）、空腹血糖（FPG）、糖化血紅蛋白（HbA1c）、簡(jiǎn)明健康狀況調(diào)查量表（SF-36）評(píng)分、胰島素抵抗指數(shù)（HOMA-IR）、網(wǎng)膜素-1（Omentin-1）、胰升血糖素樣肽-1（GLP-1）、白細(xì)胞介素-1β（IL-1β）、成纖維細(xì)胞生長(zhǎng)因子-21（FGF-21）水平。結(jié)果 治療12周后，治療組總有效率是96.00%，顯著高于對(duì)照組總有效率82.00%（P＜0.05）。治療后，兩組2 hPBG、FPG、HbA1c水平均較治療前顯著降低（P＜0.05）；治療后，與對(duì)照組對(duì)比，治療組患者2 hPBG、FPG、HbA1c指標(biāo)均更低（P＜0.05）。治療后，兩組HOMA-IR顯著降低，SF-36評(píng)分升高（P＜0.05）；治療后，與對(duì)照組對(duì)比，治療組的HOMA-IR降低，且SF-36評(píng)分升高（P＜0.05）。治療后，兩組Omentin-1、GLP-1水平較同組治療前顯著升高，而IL-1β、FGF-21水平顯著降低（P＜0.05）；治療后，治療組Omentin-1、GLP-1水平高于對(duì)照組，IL-1β、FGF-21水平低于對(duì)照組（P＜0.05）。結(jié)論 艾托格列凈聯(lián)合沙格列汀治療2型糖尿病具有顯著的臨床療效，可以較好的降低血糖相關(guān)指標(biāo)，提高患者生活質(zhì)量水平，調(diào)節(jié)炎癥反應(yīng)，具有臨床應(yīng)用價(jià)值。

Objective To explore the clinical study of etoglitazone combined with shagliptin in treatment of type 2 diabetes. Methods 100 Patients with type 2 diabetes admitted to Longquanyi District Traditional Chinese Medicine Hospital of Chengdu from January 2023 to July 2024 were selected and divided into control group and treatment group according to the random number method, with 50 cases in each group. Patients in the control group were given oral Saxagliptin Tablets, 5 mg each time, once daily. Patients in the treatment group orally took Etogliflozin Tablets, 5 mg each time, once daily on the basis of control group. The effects of two groups were observed after 12 weeks of treatment. The level of 2 hPBG, FPG, HbA1c, SF-36 score, HOMA-IR, Omentin-1, GLP-1, IL-1β, FGF-21 in two groups were compared. Results After 12 weeks of treatment, the total effective rate of treatment group was 96.00%, significantly higher than 82.00% of control group (P < 0.05). After treatment, the levels of 2 hPBG, FPG, and HbA1c in both groups were significantly lower than those before treatment (P < 0.05). After treatment, compared with the control group, 2 hPBG, FPG, and HbA1c in the treatment group were all lower (P < 0.05). After treatment, HOMA-IR in both groups decreased significantly, but the SF-36 score increased (P < 0.05). After treatment, compared with the control group, the HOMA-IR of the treatment group decreased, and the SF-36 score increased (P < 0.05). After treatment, the levels of Omentin-1 and GLP-1 in both groups were significantly increased compared with those before treatment in the same group, but the levels of IL-1β and FGF-21 were significantly decreased (P < 0.05). After treatment, the levels of Omentin-1 and GLP-1 in the treatment group were higher than those in the control group, and the levels of IL-1β and FGF-21 were lower than those in the control group (P < 0.05). Conclusion Etogliflozin combined with saxagliptin has a significant clinical efficacy in the treatment of type 2 diabetes, and can effectively lower blood sugar-related indicators, improve the life quality of patients, and regulate inflammatory responses, which has clinical application value.

R977

成都市醫(yī)學(xué)科研課題立項(xiàng)項(xiàng)目（2023273）